• No results found

[PDF] Top 20 RACK1 overexpression is linked to acquired imatinib resistance in gastrointestinal stromal tumor

Has 10000 "RACK1 overexpression is linked to acquired imatinib resistance in gastrointestinal stromal tumor" found on our website. Below are the top 20 most common "RACK1 overexpression is linked to acquired imatinib resistance in gastrointestinal stromal tumor".

RACK1 overexpression is linked to acquired imatinib resistance in gastrointestinal stromal tumor

RACK1 overexpression is linked to acquired imatinib resistance in gastrointestinal stromal tumor

... of RACK1 can simultaneously interact with different signaling molecules, allowing RACK1 to integrate inputs from distinct signaling pathways ...that RACK1 interacts with ABL, another major target of ... See full document

10

Update on imatinib for gastrointestinal stromal tumors: duration of treatment

Update on imatinib for gastrointestinal stromal tumors: duration of treatment

... of imatinib failure is acquired secondary resistance mutations or ...whether acquired resistance to imatinib in patients with advanced GIST can be delayed, the French Sarcoma ... See full document

13

Original Article Inhibition effect of Peg-IFNα-2b and Imatinib alone or combination on imatinib-resistant gastrointestinal stromal tumors cell lines

Original Article Inhibition effect of Peg-IFNα-2b and Imatinib alone or combination on imatinib-resistant gastrointestinal stromal tumors cell lines

... the Imatinib sen- sitive GIST-T1 and the Imatinib sensitive GIST- T1 cell line to simulate the acquired drug-resis- tance course of the gastrointestinal stromal tumor with alone ... See full document

8

BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance

BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance

... paraffin-embedded tumor tissue and subjected to polymerase chain reaction (PCR) amplifications of KIT exons 9, 11, 13, and 17 as well as PDGFRA exons 12 and ...adjuvant imatinib therapy (400 mg once daily). ... See full document

6

Small intestinal gastrointestinal stromal tumor in a young adult woman: a case report and review of the literature

Small intestinal gastrointestinal stromal tumor in a young adult woman: a case report and review of the literature

... to imatinib in patients with GIST mainly depends on the mutational status of KIT or PDGFRA ...with imatinib for advanced GIST will sec- ondarily develop progressive disease under ...of acquired ... See full document

7

Effect of imatinib on plasma glucose concentration in subjects with chronic myeloid leukemia and gastrointestinal stromal tumor

Effect of imatinib on plasma glucose concentration in subjects with chronic myeloid leukemia and gastrointestinal stromal tumor

... received imatinib for 6 months: 76 with normal fasting glucose concentra- tions < 100 mg/dL (normal FG), 19 subjects with glucose concentrations ≥100 to < 126 mg/dL (IFG), and 11 subjects with glucose ... See full document

8

Massive Intra-Abdominal Imatinib-Resistant Gastrointestinal Stromal Tumor in a 21-Year-Old Male

Massive Intra-Abdominal Imatinib-Resistant Gastrointestinal Stromal Tumor in a 21-Year-Old Male

... cited. Gastrointestinal stromal tumors (GISTs) in adolescence are far less common than adult GISTs and have varied GIST genotypes that present diagnostic and therapeutic ...unresectable, imatinib- ... See full document

6

Primary gastrointestinal stromal tumor of the liver: a case report and review of the literature

Primary gastrointestinal stromal tumor of the liver: a case report and review of the literature

... the gastrointestinal tract, and they have not been identified in the ...extra-gastrointestinal stromal tumors and con- cluded that with the discovery and characterization of pancreatic TCs, the ... See full document

6

Gastrointestinal Stromal Tumors  in the 21st Century

Gastrointestinal Stromal Tumors in the 21st Century

... to overexpression of aberrant transcription factors resulting in hypoxia-associated tumorigenesis and an- giogenesis, referred to as “hypoxic drive” or “pseudohypoxia ... See full document

29

Predictive Factors of Response to Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs): A Multi-Institutional Study

Predictive Factors of Response to Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs): A Multi-Institutional Study

... sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Correlation of computed tomography and 392[r] ... See full document

15

Gastrointestinal stromal tumor

Gastrointestinal stromal tumor

... of Imatinib is not determined, but the current data show no added benefit with doses greater than 400 ...of Imatinib suggest that doses of 400- 800 mg/day are safe, efficacious and patients tolerate it ... See full document

9

A rare cause of upper GI bleed

A rare cause of upper GI bleed

... characteristics of smooth muscle cells (Mazur et al 1983). Although stomach is the most common site, they may occur anywhere along the GI tract. They usually occur in middle age but may occur rarely in children as a part ... See full document

5

Gynecomastia during imatinib mesylate treatment for gastrointestinal stromal tumor: a rare adverse event

Gynecomastia during imatinib mesylate treatment for gastrointestinal stromal tumor: a rare adverse event

... of imatinib mesylate in the treat- ment of advanced and recurrent gastrointestinal tumors (GISTs) has been confirmed by clinical trials in the past ...wide. Imatinib mesylate is well tolerated with ... See full document

5

&lt;p&gt;Chloroquine Combined with Imatinib Overcomes Imatinib Resistance in Gastrointestinal Stromal Tumors by Inhibiting Autophagy via the MAPK/ERK Pathway&lt;/p&gt;

<p>Chloroquine Combined with Imatinib Overcomes Imatinib Resistance in Gastrointestinal Stromal Tumors by Inhibiting Autophagy via the MAPK/ERK Pathway</p>

... and imatinib has achieved almost complete remission in the treatment of imatinib-resistant chronic myeloid ...with imatinib alone therapy. 14 Combining imatinib and autophagy inhibition is a ... See full document

9

Update on management of GIST and postsurgical use of imatinib

Update on management of GIST and postsurgical use of imatinib

... The exact incidence of GIST is hard to determine. Recent studies report an incidence of about 10–15 cases/million/ year in Europe. However, the prevalence of GIST is higher, because many patients live for a number of ... See full document

9

Efficacy and Tolerability of Imatinib Mesylate In Advanced Gastrointestinal Stromal Tumors

Efficacy and Tolerability of Imatinib Mesylate In Advanced Gastrointestinal Stromal Tumors

... receptors. Imatinib is highly active in patients with chronic myeloid leukemia and other Philadelphia chromosome–positive leukemias, in which it inhibits the dysregulated kinase activity of the BCR-ABL fusion ... See full document

6

Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib

Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib

... A wide range of newer and more potent small molecule TKI that target KIT and/or PDGRA are in development. An agent with interesting single agent activity is sorafenib. Sorafenib is a multi-targeted small molecule TKI ... See full document

13

Case Report Gastrointestinal stromal tumor masquerading as an adrenal tumor: a case report with literature review

Case Report Gastrointestinal stromal tumor masquerading as an adrenal tumor: a case report with literature review

... It can be difficult to determine the biological behavior of GISTs, ranging from benign to malig- nant. However, their prognosis is considered to be associated with tumor size, mitotic rate, and location of the ... See full document

5

Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives

Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives

... had presented imatinib resistance or intolerance. A total of 302 patients were randomly assigned 2:1 to receive sunitinib at doses established in phase I (n: 207) or placebo (n: 105). However, the trial was ... See full document

10

Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)

Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)

... of tumor de- creased from ...drug resistance was ...mean tumor size reduction and location of tumor ...tial tumor maximum diameter ...the tumor tended to shrink greatly, but ... See full document

7

Show all 10000 documents...